G1 Therapeutics, Inc and Bionical Emas Launch Expanded Access Program for Trilaciclib in Small Cell Lung Cancer in the United States
Four things to think about: PVG in EAPs
By Nisha Vora - Senior Project Manager, Pharmacovigilance
Nuances in Pharmacovigilance case processing in Early Access Programs
By Harry Woods - Pharmacovigilance Associate
What does Early Access actually mean?
Naomi Litchfield, Patient Advocacy Manager for Bionical Emas, discusses the basic principles of Early Access Programs
Let’s Face This Together: Bionical Emas supports rare disease charity, Same But Different
How have Bionical Emas adapted as a business during COVID-19?
An interview with Kathleen DeHaven, Director of Clinical Operations North America